Company: CGCT
Filing Date: 2025-03-21
Form Type: S-1/A
Source: 0001104659-25-026623
Chunk: 157

Company: Cartesian Growth Corp III
Filing Date: 2025-03-21
Form: S-1/A
Chunk 157
---
 will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition at such
time. There is no certainty we will be in a position to, or decide to, pay cash dividends after completing any business combination.
If we increase or decrease the size of this offering pursuant to Rule 462(b) under the Securities Act, we will effect a share
capitalization or other appropriate mechanism immediately prior to the consummation of this offering in such amount as to maintain the
number of founder shares at 20% of our issued and outstanding ordinary shares upon the consummation of this offering. Further, if we
incur any indebtedness in connection with our initial business combination, our ability to declare dividends following completion of
our initial business combination may be limited by restrictive covenants we may agree to in connection therewith.

<div align='center'>84

Dilution</div>

The difference between the public offering price
per unit and the NTBV per Class A ordinary share after this offering constitutes the dilution to investors in this offering. NTBV
per share is determined by dividing our NTBV, which is our total tangible assets less total liabilities (including the value of Class A
ordinary shares that may be redeemed for cash), by the number of outstanding Class A ordinary shares.

The below calculations (A) assume that (i) no
ordinary shares are issued to shareholders of a potential business combination target as consideration or issuable by a post-business
combination company, for instance under an equity or employee share purchase plan, (ii) no ordinary shares and convertible equity
or debt securities are issued in connection with additional financing that we may seek in connection with an initial business combination,
(iii) no working capital loans are converted into private placement-equivalent warrants, as further described in this prospectus
and (iv) no value is attributed to the warrants (however, we may need to issue ordinary shares or convertible equity or debt securities
in the circumstances described above, as we intend to target an initial business combination with a target company whose enterprise value
is greater than the net proceeds of this offering and the sale of private placement warrants) and (B) assume the issuance of 20,000,000
Class A ordinary shares (or 23,000,000 Class A ordinary shares if the underwriters’ over-allotment option is exercised
in full) and 5,750,000 founder shares (up to 750,000 of which are assumed to be forfeited in the